| Autor: |
Hansen, T. K., Ankersen, M., Hansen, B. S., Raun, K., Nielsen, K. K., Lau, J., Peschke, B., Lundt, B. F., Thogersen, H., Johansen, N. L., Madsen, K., Andersen, P. H. |
| Zdroj: |
Journal of Medicinal Chemistry; September 10, 1998, Vol. 41 Issue: 19 p3705-3714, 10p |
| Abstrakt: |
A novel class of growth hormone-releasing compounds with a molecular weight in the range from 500 to 650 has been discovered. The aim of this study was to obtain growth hormone secretagogues with oral bioavailability. By a rational approach we were able to reduce the size of the lead compound ipamorelin (4) and simultaneously to reduce hydrogen-bonding potential by incorporation of backbone isosters while retaining in vivo potency in swine. A rat pituitary assay was used for screening of all compounds and to evaluate which compounds should be tested further for in vivo potency in swine and oral bioavailability, fpo, in dogs. Most of the tested compounds had fpo in the range of 10−55%. In vivo potency in swine after iv dosing is reported, and ED50 was found to be 30 nmol/kg of body weight for the most potent compound. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
